Attention-Deficit/Hyperactivity Disorder
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Drug Toxicity: Risk factors
Pharmacovigilance
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Alain Lesage1, Johanne Renaud2, Édouard Kouassi3
1Quebec Suicide, Mood Disorders and Associated Disorders Research Network, Montreal, Canada; Department of Psychiatry, University of Montreal, QC, Canada; Institut Universitaire en Santé Mentale de Montréal, 7401 Hochelaga, Montreal QC H1N 3M5, Canada.
No abstract available in PubMed .
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020